We expand upon this knowledge by demonstrating that tumor-associated distal lymphatics downstream of SLNs undergo functional and structural remodeling during disease progression, which can be mitigated via treatment with function blocking antibodies to VEGF-C or NRP2, but not VEGF-A. Here, VEGFC is linked to neoplasm.